CytomX Therapeutics, Inc. Accounts Payable
CytomX Therapeutics, Inc. (CTMX) had Accounts Payable of $1.94 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $1.94M.
- 2026-03-31: Accounts Payable, Current $1.37M.
- 2025-12-31: Accounts Payable, Current $1.30M.
- 2025-09-30: Accounts Payable, Current $646.00K.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $1.94M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.37M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.30M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $646.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $227.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $276.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.09M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.42M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $611.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.96M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.46M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.71M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.03M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $2.20M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.81M 10-K · filed 2024-03-11 |
| 2022-09-30 | $5.18M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.92M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.72M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $2.82M 10-K/A · filed 2023-03-27 |
| 2021-09-30 | $1.52M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.75M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.58M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $3.00M 10-K/A · filed 2023-03-27 |
| 2020-09-30 | $3.64M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $4.93M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $3.78M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $4.16M 10-K · filed 2021-02-24 |
| 2019-09-30 | $4.55M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $4.52M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $9.51M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $5.13M 10-K · filed 2020-02-27 |
| 2018-09-30 | $6.87M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $4.24M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $5.35M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $4.21M 10-K · filed 2019-02-27 |
| 2017-09-30 | $2.87M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $6.36M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $3.70M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $6.60M 10-K · filed 2018-03-07 |
| 2016-09-30 | $517.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $1.43M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $4.96M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $4.70M 10-K · filed 2017-03-02 |
| 2015-09-30 | $2.70M 10-Q · filed 2015-11-23 |
| 2014-12-31 | $1.92M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |